Brief: EQRx Announces Acceptance Of Marketing Authorization Application By The UK'S Medicines And Healthcare Products Regulatory Agency For Aumolertinib In EGFR-Mutated Non-Small Cell Lung Cancer
14/06/2022 12:27
June 14 (Reuters) - EQRx Inc EQRX.O :
* EQRX ANNOUNCES ACCEPTANCE OF MARKETING AUTHORIZATION
APPLICATION
BY THE UK'S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
FOR AUMOLERTINIB IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nGNX7d1bMR
Further company coverage: EQRX.O
Recent news on EQRx
See all newsBrief: Leading Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Revolution Medicines Stockholders Vote "FOR" Proposed Acquisition Of EQRx, Inc
Brief: Revolution Medicines Inc Says Will Acquire EQRx In An All-Stock Transaction
U.S. RESEARCH ROUNDUP- Cigna Group, McKesson, Zscaler
Brief: EQRx posts Q1 EPS USD -0.17
Brief: EQRx Says Jami Rubin Will Step Down As Chief Financial Officer